Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen

AIDS

Volumn 25, Issue 17, 2011, Pages 2143-2148

  Larrouy, Lucile ^a   Charpentier, Charlotte ^a   Landman, Roland ^b   Capitant, Catherine ^c   Chazallon, Corine ^c   Yeni, Patrick ^b   Peytavin, Gilles ^a   Damond, Florence ^a   Brun Vezinet, Françoise ^a   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

Author keywords

Gag; Gag pol frameshift; HIV quasispecies; Protease inhibitor; Resistance

Indexed keywords

ATAZANAVIR; FOSAMPRENAVIR; GAG PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CASE REPORT; DRUG TREATMENT FAILURE; FRAMESHIFT MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; VIROLOGY;

CLONE CELLS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT FAILURE;

EID: 80055057230     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834cabb9     Document Type: Article

References (16)

1. Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, et al. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-I HIV-1-infected patients: the 2IP ANRS 127 study. J Antimicrob Chemother 2009; 64:118-125.
2. Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, et al. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral- na?̈ve HIV-infected patients. Antimicrob Agents Chemother 2010; 54:2910-2919.
3. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
4. Marcelin A-G, Flandre P, de Mendoza C, Roquebert B, Peytavin G, Valer L, et al. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Antivir Ther 2007; 12:247-252. (Pubitemid 46569909)
5. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-I subjects in the CASTLE study. PLoS One 2010; 5:e10952.
6. Lataillade M, Chiarella J, Yang R, Uy J, St John E, Simen B, Kozal M. Prevalence and clinical significance of raltegravir (RAL) and atazanavir (ATV) resistance mutations by ultra-deep sequencing (UDS) in HIV-infected antiretretoviral-naive subjects in the SPARTAN study. International Workshop HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Antiviral Therapy, Los Cabos, Mexico, 7-11 June 2011; [abstract 26].
7. Callebaut CS, Stray K, Tsai L, Xu L, Lee W, Cihlar T. In vitro HIV- 1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. XVI International HIV Drug Resistance Workshop, Antiviral Therapy, Barbados, 12-16 June 2007; [abstract 16].
8. Doyon L, Payant C, Brakier-Gingras L, Lamarre D. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 1998; 72:6146-6150. (Pubitemid 28283405)
9. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, et al. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 2007; 54:367-374. (Pubitemid 46395023)
10. Ghosn J, Delaugerre C, Flandre P, Galimard J, Raffi F, Norton M, et al. Baseline number of substitutions in p2/NC site of gag gene is predictive of virological failure in patients randomized to first-line lopinavir/ritonavir single-drug regimen: week-96 results of the MONARK trial. 16th Conference on Retroviruses and Opportunistic Infections, Montréal, Canada, 8-11 February 2009; [abstract 630]
11. Nijhuis M, Schipper P, King M, Bernstein B, Hanna G, Boucher CAB. Changes in HIV gag and protease cannot explain persistent viraemia in the majority of patients failing first-line lopinavir/ ritonavir therapy. XVI International HIV Drug Resistance Workshop, Antiviral Therapy, Barbados, 12-16 June 2007; [abstract 133]
12. Parkin N, Chappey C, Lam E, Petropoulos C. Reduced susceptibility to protease inhibitors (PI) in the absence of primary PI resistance-associated mutations. XIV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Antiviral Therapy, Québec City, Québec, Canada, 7-11 June 2005; [abstract 108]
13. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009; 5: e1000345.
14. Lillemark MR, Gerstoft J, Obel N, Kronborg G, Pedersen C, Joørgensen LB, et al. Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen. J Med Virol 2011; 83:377-383.
15. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76:7398-7406. (Pubitemid 34760962)
16. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7637. (Pubitemid 28377901)